Mainz Biomed (NASDAQ:MYNZ) Coverage Initiated at Maxim Group

Maxim Group initiated coverage on shares of Mainz Biomed (NASDAQ:MYNZ) in a research report sent to investors on Friday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $14.00 price target on the stock.

Separately, HC Wainwright cut shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a research note on Monday, November 25th.

Mainz Biomed Price Performance

MYNZ stock opened at $6.04 on Friday. Mainz Biomed has a 12 month low of $3.65 and a 12 month high of $45.60. The firm has a 50 day moving average of $5.32 and a two-hundred day moving average of $9.35.

Institutional Trading of Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC acquired a new position in Mainz Biomed (NASDAQ:MYNZ) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned about 0.92% of Mainz Biomed at the end of the most recent quarter.

Mainz Biomed Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.